Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, Orange, California, USA.
Department of Pediatrics, New York Medical College, Valhalla, New York, USA.
Am J Hematol. 2024 May;99(5):910-921. doi: 10.1002/ajh.27204. Epub 2024 Jan 25.
Effective cellular therapy using CD19 chimeric antigen receptor T-cells for the treatment of advanced B-cell malignancies raises the question of whether the administration of adoptive cellular therapy (ACT) posttransplant could reduce relapse and improve survival. Moreover, several early phase clinical studies have shown the potential beneficial effects of administration of tumor-associated antigen-specific T-cells and natural killer cells posttransplant for high-risk patients, aiming to decrease relapse and possibly improve survival. In this article, we present an in-depth review of ACT after transplantation, which has the potential to significantly improve the efficacy of this procedure and revolutionize this field.
使用嵌合抗原受体 T 细胞治疗 CD19 治疗晚期 B 细胞恶性肿瘤的有效细胞疗法引发了这样一个问题，即移植后是否可以进行过继性细胞治疗 (ACT) 以降低复发率并提高生存率。此外，几项早期临床研究表明，移植后给予肿瘤相关抗原特异性 T 细胞和自然杀伤细胞可能对高危患者有益，旨在降低复发率并可能改善生存。在本文中，我们对移植后的 ACT 进行了深入回顾，ACT 有可能显著提高该程序的疗效并彻底改变这一领域。
